| Literature DB >> 35656163 |
Akosua Dufie Ankomah1, Yaw Duah Boakye1, Theresah Appiah Agana1, Vivian Etsiapa Boamah1, Paul Poku Sampene Ossei2, Francis Adu1, Christian Agyare1.
Abstract
Cnestisferruginea is a tropical plant, which is traditionally used in the treatment and management of various conditions including skin infections and wounds. The aim of this study was to investigate the dermal toxicity and wound healing potential of C. ferruginea. Ten millimeter full-thickness mucosal wounds were created on the dorsal midportion of the Sprague Dawley rats. Wounds were treated with 10, 5, and 2.5% w/w aqueous creams, prepared from the methanol extract of the root bark of C. ferruginea (CFM). The wound tissues were harvested on day 21 for histology studies. Compared with the untreated group, 10, 5, and 2.5% w/w CFM-treated wounds significantly reduced the wound size over the study period (P < 0.0001). Tissue histology revealed a healed wound with well-regenerated collagen and skin appendages with no pus cells. A skin irritation test was conducted on CFM, as well as the dermal toxicity of CFM was determined in the repeated dose and acute dermal toxicity bioassays. These tests revealed that CFM showed no toxic effect on the skin and showed that CFM was not a skin irritant. C. ferruginea exhibited wound healing activity, which gives credence to its folkloric use.Entities:
Year: 2022 PMID: 35656163 PMCID: PMC9152407 DOI: 10.1155/2022/5268613
Source DB: PubMed Journal: Adv Pharmacol Pharm Sci ISSN: 2633-4690
Draize dermal irritation scoring system.
| Score | Translation |
|---|---|
| 0 | No erythema or oedema |
| 1 | Very inappreciable oedema or erythema |
| 2 | Small oedema with raised skin at the edges of the area |
| 3 | Moderate to severe erythema or oedema |
| 4 | Severe erythema or oedema |
Phytochemical test performed on the root bark extract of C. ferruginea.
| Secondary metabolite | Test performed | Reference |
|---|---|---|
| Tannins | Ferric chloride test | Boakye et al. [ |
| Saponins | Foaming/frothing test | Boakye et al. [ |
| Glycosides | Fehling's test | Evans, [ |
| Terpenoids | Acetic anhydride test | Evans, [ |
| Steroids | Libermann–Burchard's test | Shaikh and Patil [ |
| Alkaloids | Dragendorff's/Kraut's test | Boakye et al. [ |
| Flavonoids | Lead acetate test | Shaikh and Patil [ |
| Coumarins | NaOH paper test | Shaikh and Patil [ |
Figure 1Weekly average weight of rats over 14-day study period.
Relative organ weight of rats after the 14-day study period.
| Organs | Relative organ weight | |
|---|---|---|
| Control | 2000 mg/kg/day | |
| Kidney | 0.88 ± 0.03 | 0.89 ± 0.02 |
| Liver | 3.47 ± 0.02 | 3.46 ± 0.04 |
| Brain | 2.42 ± 0.03 | 2.45 ± 0.03 |
| Spleen | 0.33 ± 0.01 | 0.32 ± 0.02 |
| Heart | 0.46 ± 0.02 | 0.46 ± 0.03 |
| Lungs | 0.80 ± 0.04 | 0.79 ± 0.04 |
Values expressed as mean ± SEM, n = 5 female rats. Comparison of CFM at 2000 mg/kg/day to control indicates significance levels of P=0.25 (Wilcoxon matched-pairs signed-rank test).
Average weight of rats over 21-day study period.
| Group | Weights (g) of rats over 21-day study period | ||||||
|---|---|---|---|---|---|---|---|
| Week 0 |
| Week 1 |
| Week 2 |
| Week 3 | |
| Control | 275.37 ± 8.42 |
| 277.57 ± 8.94 |
| 280.30 ± 9.41 |
| 282.43 ± 9.81 |
| TG-1 | 272.41 ± 8.17 |
| 274.06 ± 8.88 |
| 275.51 ± 9.37 |
| 279.06 ± 7.46 |
| TG-2 | 275.26 ± 11.23 |
| 276.62 ± 11.83 |
| 278.65 ± 12.04 |
| 281.37 ± 11.33 |
| TG-3 | 277.61 ± 9.97 |
| 279.77 ± 9.81 |
| 281.84 ± 9.82 |
| 283.94 ± 10.02 |
TG-1: 250 mg/kg/day, TG-2: 500 mg/kg/day, TG-3: 1000 mg/kg/day, TG: CFM-treated group, CG: control group. Values expressed as mean ± SEM, n = 10 (one-way ANOVA).
Relative organ weight of rats treated with different doses of extract for 21 days.
| Organs | Control | Relative organ weight of CFM-treated rats | |||||
|---|---|---|---|---|---|---|---|
| 250 mg/kg |
| 500 mg/kg |
| 1000 mg/kg |
| ||
| Kidney | 0.87 ± 0.03 | 0.86 ± 0.03 |
| 0.87 ± 0.03 |
| 0.89 ± 0.01 |
|
| Liver | 3.46 ± 0.02 | 3.44 ± 0.01 |
| 3.45 ± 0.02 |
| 3.44 ± 0.04 |
|
| Brain | 2.45 ± 0.03 | 2.43 ± 0.05 |
| 2.44 ± 0.03 |
| 2.45 ± 0.02 |
|
| Spleen | 0.31 ± 0.01 | 0.31 ± 0.01 |
| 0.31 ± 0.01 |
| 0.32 ± 0.02 |
|
| Heart | 0.45 ± 0.03 | 0.44 ± 0.02 |
| 0.44 ± 0.02 |
| 0.45 ± 0.03 |
|
| Lungs | 0.81 ± 0.01 | 0.80 ± 0.02 |
| 0.79 ± 0.04 |
| 0.79 ± 0.05 |
|
Values expressed as mean ± SEM, n = 10 (one-way ANOVA).
Haematological parameters for the toxicity test.
| Test | Control | CFM | |||||
|---|---|---|---|---|---|---|---|
| 250 mg/kg |
| 500 mg/kg |
| 1000 mg/kg |
| ||
| RBCs (106/ | 8.10 ± 0.6 | 8.12 ± 0.5 |
| 8.0 ± 1.1 |
| 7.94 ± 1.1 |
|
| HB (g/dL) | 14.5 ± 1.2 | 14.3 ± 1.1 |
| 13.9 ± 1.6 |
| 13.8 ± 1.3 |
|
| HCT (%) | 47.2 ± 1.1 | 47.2 ± 0.6 |
| 46.9 ± 1.2 |
| 47.5 ± 2.1 |
|
| MCV ( | 58.3 ± 2.3 | 58.3 ± 3.3 |
| 58.1 ± 1.0 |
| 57.1 ± 1.6 |
|
| MCH (pg) | 17.6 ± 0.7 | 18.2 ± 0.1 |
| 17.4 ± 1.2 |
| 17.2 ± 2.1 |
|
| MCHC (g/dL) | 30.7 ± 1.4 | 30.7 ± 1.4 |
| 29.9 ± 1.0 |
| 32.4 ± 1.5 |
|
| Platelets (103/ | 836 ± 14.1 | 835 ± 14.1 |
| 843 ± 12.1 |
| 864 ± 15.2 |
|
| WBCs (103/ | 9.4 ± 3.1 | 9.4 ± 3.2 |
| 8.78 ± 0.9 |
| 8.9 ± 5.3 |
|
RBCs: red blood cells, HB: haemoglobin, HCT: haematocrit, MCV: mean corpuscular volume, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration, WBCs: white blood cells. Level of significance: values expressed as mean ± SEM, n = 10 (one-way ANOVA).
Biochemical analysis of the serum.
| Test | Control | CFM | |||||
|---|---|---|---|---|---|---|---|
| 250 mg/kg |
| 500 mg/kg |
| 1000 mg/kg |
| ||
| Albumin (g/dL) | 21.5 ± 1.7 | 21.5 ± 1.8 |
| 22.6 ± 2.1 |
| 22.7 ± 2.3 |
|
| ALP (U/L) | 198.4 ± 0.8 | 197.4 ± 0.5 |
| 198.3 ± 1.6 |
| 198.0 ± 1.2 |
|
| AST (U/L) | 353.3 ± 1.4 | 353.3 ± 1.6 |
| 354.5 ± 2.9 |
| 353.6 ± 1.8 |
|
| ALT (U/L) | 130.6 ± 2.2 | 131.6 ± 2.1 |
| 129.2 ± 2.1 |
| 129.0 ± 1.1 |
|
| GGT (U/L) | <6.0 | <6.0 |
| <6.0 |
| <6.0 |
|
| IND BIL ( | 1.3 ± 0.01 | 1.4 ± 0.1 |
| 1.3 ± 0.02 |
| 1.2 ± 1.3 |
|
ALP: alkaline phosphate, AST: aspartate transaminase, ALT: alanine transaminase, GGT: gamma-glutamyl transferase, IND BIL: indirect bilirubin. Values expressed as mean ± SEM, n = 10 (one-way ANOVA).
Figure 2Histology of skin tissues after 21-day toxicity study period. (a) Skin tissue of control animal, (b) skin tissue of CFM-treated rat at 250 mg/kg, (c) skin tissue of CFM-treated rat at 500 mg/kg, and (d) skin tissue of CFM-treated rat at 1000 mg/kg. Picture note. CS: collagen strands; BV: blood vessels; SA: skin appendages; E: epithelium; MC: muscle cell.
Figure 3Influence of CFM on the rate of contraction of excision wounds. (a) Time-course curve of CFM on wound contraction expressed as percentage. (b) AUC of percentage wound contraction.
Figure 4Histological images (x40) from the wound healing activity. (a) Untreated wound tissues, (b) base (aqueous cream only)-treated tissues, (c) 2.5% w/w CFM-treated wounds tissues, (d) 5% w/w CFM-treated wounds tissues, (e) 10% w/w CFM-treated wound tissues, and (f) 1% w/w silver sulphadiazine-treated wound tissues. Picture note. CS: collagen strands; BV: blood vessels; RBVs: ruptured blood vessels; PCs: pus cells; SA: skin appendages; E: epithelium.
Phytochemical composition of CFM.
| Secondary metabolite | CFM |
|---|---|
| Tannins | + |
| Glycosides | + |
| Saponins | + |
| Flavonoids | + |
| Coumarins | + |
| Steroids | − |
| Terpenoids | + |
| Alkaloids | + |
+presence of phytochemical, − absence of phytochemical.